Sol-Gel Technologies (SLGL) Net Margin (2018 - 2026)
Sol-Gel Technologies (SLGL) posted quarterly Net Margin of 3450.93% for Q1 2026, up 259661.0% year-over-year from N/an in Q1 2025, and up 138.79% quarter-over-quarter from 8895.83% in Q4 2025.
Sol-Gel Technologies (SLGL) Net Margin (2018 - 2026) Analysis & Trends
Sol-Gel Technologies (SLGL) has reported Net Margin for 9 consecutive years, with 3450.93% the latest figure, recorded in Q1 2026.
- In Q1 2026, Net Margin rose 259661.0% year-over-year to 3450.93%; the TTM figure through Mar 2026 stood at 349.18% (up 4666.0% YoY), while the FY2025 annual figure was 340.63%, up 19502.0% from the prior year.
- Net Margin advanced to 3450.93% in Q1 2026 per SLGL's latest filing, from 8895.83% in the prior quarter.
- Across five years, Net Margin topped out at 3450.93% in Q1 2026 and bottomed at 20103.96% in Q4 2024.
- Historically, Net Margin has averaged 2726.08% across 5 years, with a median of 0.0% in 2022.
- Annual changes were most pronounced in 2023 — Net Margin sank 1192819 bps — and 2025, when it soared 1120812 bps.
- Sol-Gel Technologies' Net Margin stood at 0.0% in 2022, then plunged by 2000000000 bps to 11928.19% in 2023, then slumped by 69 bps to 20103.96% in 2024, then soared by 56 bps to 8895.83% in 2025, then soared by 139 bps to 3450.93% in 2026.
- Business Quant data shows SLGL's Net Margin at 3450.93% in Q1 2026, 8895.83% in Q4 2025, and 1572.0% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Sol-Gel Technologies | 240.26 Mn | 230.12 Mn | - | 3,569.44% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3,450.93% |
| Dec 31, 2025 | -8,895.83% |
| Sep 30, 2025 | -1,572.00% |
| Jun 30, 2025 | 0.00% |
| Mar 31, 2025 | 854.32% |
| Dec 31, 2024 | -20,103.96% |
| Sep 30, 2024 | -15.44% |
| Jun 30, 2024 | 0.00% |
| Dec 31, 2023 | -11,928.19% |
| Sep 30, 2023 | -2,681.22% |
| Jun 30, 2023 | 0.00% |
| Dec 31, 2022 | 0.00% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | 0.00% |
| Mar 31, 2022 | 0.19% |
| Dec 31, 2021 | 0.00% |
| Sep 30, 2021 | 0.00% |
| Jun 30, 2021 | 0.00% |
| Mar 31, 2021 | 579.60% |
| Dec 31, 2020 | 0.00% |